AU2008360937B9 - Methods of enhancing adjuvanticity of vaccine compositions - Google Patents

Methods of enhancing adjuvanticity of vaccine compositions Download PDF

Info

Publication number
AU2008360937B9
AU2008360937B9 AU2008360937A AU2008360937A AU2008360937B9 AU 2008360937 B9 AU2008360937 B9 AU 2008360937B9 AU 2008360937 A AU2008360937 A AU 2008360937A AU 2008360937 A AU2008360937 A AU 2008360937A AU 2008360937 B9 AU2008360937 B9 AU 2008360937B9
Authority
AU
Australia
Prior art keywords
cells
vaccine
pbs57
ova
pbs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008360937A
Other languages
English (en)
Other versions
AU2008360937B2 (en
AU2008360937A1 (en
AU2008360937A2 (en
Inventor
Vincent Serra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abivax SA
Original Assignee
Abivax SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax SA filed Critical Abivax SA
Publication of AU2008360937A1 publication Critical patent/AU2008360937A1/en
Publication of AU2008360937A2 publication Critical patent/AU2008360937A2/en
Assigned to WITTYCELL reassignment WITTYCELL Amend patent request/document other than specification (104) Assignors: WITTYCELL S.A.S.
Publication of AU2008360937B2 publication Critical patent/AU2008360937B2/en
Application granted granted Critical
Publication of AU2008360937B9 publication Critical patent/AU2008360937B9/en
Assigned to ABIVAX reassignment ABIVAX Request for Assignment Assignors: WITTYCELL
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2008360937A 2007-08-29 2008-08-29 Methods of enhancing adjuvanticity of vaccine compositions Ceased AU2008360937B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96873107P 2007-08-29 2007-08-29
US60/968,731 2007-08-29
PCT/IB2008/003016 WO2010023498A1 (en) 2007-08-29 2008-08-29 Methods of enhancing adjuvanticity of vaccine compositions

Publications (4)

Publication Number Publication Date
AU2008360937A1 AU2008360937A1 (en) 2010-03-04
AU2008360937A2 AU2008360937A2 (en) 2010-04-29
AU2008360937B2 AU2008360937B2 (en) 2014-01-16
AU2008360937B9 true AU2008360937B9 (en) 2014-02-13

Family

ID=42061962

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008360937A Ceased AU2008360937B9 (en) 2007-08-29 2008-08-29 Methods of enhancing adjuvanticity of vaccine compositions

Country Status (14)

Country Link
US (1) US8916164B2 (enExample)
EP (1) EP2190475B1 (enExample)
JP (1) JP5539890B2 (enExample)
KR (1) KR101540081B1 (enExample)
CN (1) CN101820909A (enExample)
AU (1) AU2008360937B9 (enExample)
BR (1) BRPI0815846A2 (enExample)
ES (1) ES2558157T3 (enExample)
HR (1) HRP20151356T1 (enExample)
PL (1) PL2190475T3 (enExample)
PT (1) PT2190475E (enExample)
RU (1) RU2491090C2 (enExample)
WO (1) WO2010023498A1 (enExample)
ZA (1) ZA201001477B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008350531B2 (en) 2007-12-05 2014-01-23 Abivax Use of glycosylceramides for enhancing the immune response to antigens
ES2617510T3 (es) 2012-04-26 2017-06-19 Riken Nuevo carbamato de glicolípido y uso del mismo
WO2022187141A1 (en) 2021-03-01 2022-09-09 Deciduous Therapeutics Compounds for activating invariant natural killer t-cells and methods of use in eliminating inflammatory senescent cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005824A1 (en) * 2006-06-30 2008-01-10 The Scripps Research Institute Adjuvants and methods of use

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (enExample) 1992-07-16 1995-11-01 Kirin Brewery
KR100281264B1 (ko) 1992-10-22 2001-02-01 마나배 게이사꾸 신규한 스핀고당 지질 및 그의 사용
CN1045302C (zh) 1993-04-15 1999-09-29 麒麟麦酒株式会社 新型(神经)鞘糖脂、含有它们的药物组合物及其用途
CA2162478A1 (en) 1993-05-14 1994-11-24 Shawn A. Defrees Sialyl lex analogues as inhibitors of cellular adhesion
US6054433A (en) 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
WO1998034623A1 (en) 1997-02-05 1998-08-13 Kirin Beer Kabushiki Kaisha Freeze-dried composition containing glycosphingolipid and process for producing the same
ES2235324T3 (es) 1997-04-10 2005-07-01 Kirin Beer Kabushiki Kaisha Empleo de a-glicosilceramidas para la obtencion de un agente terapeutico para enfermedades autoinmunes.
AU750141B2 (en) 1997-12-30 2002-07-11 A+ Science Invest Ab Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
AU765809B2 (en) 1998-02-12 2003-10-02 Emory University Sphingolipid derivatives and their methods of use
SE9900496D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
WO2001026683A2 (en) * 1999-10-12 2001-04-19 National Research Council Of Canada Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2001082935A1 (fr) 2000-04-28 2001-11-08 Orient Cancer Therapy Co.,Ltd. Remedes contre le cancer
JP4410913B2 (ja) 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
AU2001268564A1 (en) 2000-06-22 2002-01-02 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
WO2002018539A2 (en) 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
CA2453880A1 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
RU2360699C2 (ru) * 2001-10-03 2009-07-10 Новартис Вэксинес Энд Дайэгностикс Инк. Композиции менингококковых вакцин с адъювантами
CN1578667A (zh) 2001-11-06 2005-02-09 东方癌症治疗株式会社 抗癌组合物
US7273853B2 (en) 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CA2493690C (en) 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
EP1611147A4 (en) 2003-03-20 2007-10-17 Univ Brigham Young 6 "amino-6" -DEOXYGALACTOSYLCERAMIDE
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
AR056245A1 (es) * 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
US20050222048A1 (en) 2004-03-31 2005-10-06 The Research Foundation Of The City University Of New York Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
AU2005280163B2 (en) 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
DK1786439T3 (da) 2004-09-03 2010-07-12 Univ Chicago Fremgangsmåder til aktivering af NKT-celler
EP1833489A4 (en) 2004-12-28 2011-08-03 Univ Rockefeller GLYCOLIPIDES AND ANALOGUE THEREOF AS ANTIGENS FOR NK-T CELLS
US9295722B2 (en) 2005-01-28 2016-03-29 The Scripps Research Institute Bacterial glycolipid activation of CD1d-restricted NKT cells
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
WO2007050668A1 (en) 2005-10-25 2007-05-03 Ludwig Institute For Cancer Research Analogs of alpha galactosylceramide and uses thereof
SI2056842T1 (sl) 2006-04-07 2013-02-28 The Scripps Research Institute Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
EP2029165B1 (en) 2006-04-27 2014-12-03 Cellid Co., Ltd B cell-based vaccine loaded with the ligand of natural killer t cell and antigen
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
KR100868959B1 (ko) 2006-12-30 2008-11-17 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
AU2008350531B2 (en) 2007-12-05 2014-01-23 Abivax Use of glycosylceramides for enhancing the immune response to antigens
CN102215864A (zh) 2008-10-08 2011-10-12 威蒂赛尔公司 用于抗流感的疫苗组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005824A1 (en) * 2006-06-30 2008-01-10 The Scripps Research Institute Adjuvants and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU, Y., et al., "A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells," Journal of Immunological Methods, 2006, Vol. 312, No. 1-2, pages 34-39. *

Also Published As

Publication number Publication date
JP5539890B2 (ja) 2014-07-02
AU2008360937B2 (en) 2014-01-16
US8916164B2 (en) 2014-12-23
KR20100072211A (ko) 2010-06-30
KR101540081B1 (ko) 2015-07-29
RU2491090C2 (ru) 2013-08-27
AU2008360937A1 (en) 2010-03-04
AU2008360937A2 (en) 2010-04-29
US20100285042A1 (en) 2010-11-11
ZA201001477B (en) 2010-12-29
BRPI0815846A2 (pt) 2017-05-30
JP2011518760A (ja) 2011-06-30
PT2190475E (pt) 2016-02-11
WO2010023498A1 (en) 2010-03-04
RU2010111766A (ru) 2011-10-10
CN101820909A (zh) 2010-09-01
EP2190475A1 (en) 2010-06-02
HRP20151356T1 (hr) 2016-01-01
EP2190475B1 (en) 2015-10-28
PL2190475T3 (pl) 2016-04-29
WO2010023498A8 (en) 2010-04-15
ES2558157T3 (es) 2016-02-02

Similar Documents

Publication Publication Date Title
EP2231145B1 (en) Use of glycosylceramides for enhancing the immune response to antigens
AU2007269299A2 (en) Adjuvants and methods of use
DK2231196T3 (en) Increase in the immune response by peptide-antigen binding
EP2029165A1 (en) B cell-based vaccine loaded with the ligand of natural killer t cell and antigen
AU2008360937B9 (en) Methods of enhancing adjuvanticity of vaccine compositions
DK2190475T3 (en) PROCEDURES FOR IMPROVING ADJUSTABILITY IN VACCINE COMPOSITIONS

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 APR 2010

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ABIVAX

Free format text: FORMER OWNER WAS: WITTYCELL

MK14 Patent ceased section 143(a) (annual fees not paid) or expired